Secukinumab-Induced Lymphocytic Colitis

J Investig Med High Impact Case Rep. 2022 Jan-Dec:10:23247096221110399. doi: 10.1177/23247096221110399.


Secukinumab an interleukin-17 (IL-17) monoclonal antibody inhibitor is currently approved for the treatment of rheumatological conditions, such as psoriasis and ankylosing spondylitis. Lymphocytic colitis, a phenotype of microscopic colitis, is a long-term inflammatory condition, is characterized by relapsing diarrhea. The specific entity of drug-induced lymphocytic colitis has been discussed with numerous individual cases being reported from around the world. Secukinumab has been linked with exacerbation of and de novo cases of inflammatory bowel disease. However, lymphocytic colitis in association with this drug has not been documented. The management of drug-induced lymphocytic colitis is complicated, as patients frequently exhibit spontaneous remission of symptoms. Removal of the offending agent has shown some benefit; however, some patients continue to exhibit symptoms months after drug cessation and washout. Although our patient's lymphocytic colitis was benign and responded to the cessation Secukinumab, it is an important diagnosis to consider in patients with new onset relapsing diarrhea treated with biologics.

Keywords: gastroenterology; immunology; rheumatology.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Colitis, Lymphocytic* / chemically induced
  • Colitis, Lymphocytic* / drug therapy
  • Colitis, Microscopic* / chemically induced
  • Colitis, Microscopic* / drug therapy
  • Diarrhea / chemically induced
  • Humans


  • Antibodies, Monoclonal, Humanized
  • secukinumab